EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors.
Dr. Dietz brings to Nutcracker Therapeutics nearly three decades of experience in the investment banking and pharmaceutical industries. He is currently the Chairman and CEO of Waypoint Holdings, a financial holdings and services firm. Additionally, he serves as Chairman of the Board for Eiger BioPharmaceuticals, as well as a board member of Paratek Pharmaceuticals, Leap Therapeutics, and several other private companies.
“Dr. Dietz will be a welcome addition to our board,” said Igor Khandros, Ph.D., CEO of Nutcracker Therapeutics. “His guidance and extensive experience in the financial markets and numerous pharmaceutical companies will be an asset to Nutcracker Therapeutics as we continue our course towards the company’s first clinical trial.”
Dr. Dietz began his career as a member of the research faculty at the University of California, San Francisco’s Department of Medicine. He then moved to the investment banking firm Pacific Growth Equities, where he served in various roles prior to becoming its co-CEO. The firm was eventually acquired by Wedbush Securities, from which point he served as the head of its investment banking division.
He joins Dr. Khandros, Robert Nelsen of ARCH Venture Partners and Michael Bigham of Paratek Pharmaceuticals on Nutcracker Therapeutics’ board of directors.
About Nutcracker Therapeutics, Inc.
Nutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker Therapeutics’ technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.
For more information, visit www.nutcrackerx.com.
Media Contact:
Azeem Zeekrya
HDMZ
azeem.zeekryar@hdmz.com
(312) 506-5244